Context: Contributing to the evidence base, by disseminating findings through written products such as journal articles, is a core competency for public health practitioners. Disseminating practice-based evidence that supports improving cardiovascular health is necessary for filling literature gaps, generating health policies and laws, and translating evidence-based strategies into practice. However, a gap exists in the dissemination of practice-based evidence in public health.
View Article and Find Full Text PDFThe increasing application of nanotechnology has resulted in a growing number of nano-enabled consumer products, and they could be important contributors to indoor particulate matter, with potential adverse health effects. This study investigated the exposure of adults and children to the released and resuspended manufactured particles from seven nano-enabled consumer sprays. Sedimentation and resuspension of released particles were investigated in a newly constructed 2.
View Article and Find Full Text PDFThe virally encoded 3C-like protease (3CL) is a well-validated drug target for the inhibition of coronaviruses including Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Most inhibitors of 3CL are peptidomimetic, with a γ-lactam in place of Gln at the P1 position of the pseudopeptide chain. An effort was pursued to identify a viable alternative to the γ-lactam P1 mimetic which would improve physicochemical properties while retaining affinity for the target.
View Article and Find Full Text PDFIntegration of care through digitalisation of paper records is important for childbearing women who may see multiple clinicians both within the hospital and the community. It is important that in the implementation of an EMR, the established benefits of a paper and handheld records are transferred and not lost. Acceptance and positive use of digital records in maternity settings has occurred despite concerns regarding workload interrupting women centred care.
View Article and Find Full Text PDFGSK2798745, an antagonist of the transient receptor potential vanilloid 4 (TRPV4) ion channel, was recently investigated in clinical trials for the treatment of cardiac and respiratory diseases. Human plasma and urine samples collected from healthy volunteers following oral administration were analyzed to identify circulating and excreted metabolites of the parent drug. One major circulating metabolite () was found in pooled human plasma samples, accounting for approximately half of the observed drug-related material.
View Article and Find Full Text PDF